Akoya Biosciences Inc (AKYA)
4.04
+0.05
(+1.25%)
USD |
NASDAQ |
May 03, 16:00
4.04
0.00 (0.00%)
After-Hours: 20:00
Akoya Biosciences Cash from Financing (TTM): 56.84M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 56.84M |
September 30, 2023 | 56.04M |
June 30, 2023 | 66.04M |
March 31, 2023 | 28.38M |
December 31, 2022 | 28.73M |
September 30, 2022 | 18.60M |
June 30, 2022 | 8.701M |
Date | Value |
---|---|
March 31, 2022 | 136.97M |
December 31, 2021 | 137.04M |
September 30, 2021 | 142.57M |
June 30, 2021 | 142.66M |
March 31, 2021 | 8.142M |
December 31, 2020 | 5.486M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
5.486M
Minimum
Dec 2020
142.66M
Maximum
Jun 2021
64.32M
Average
56.04M
Median
Sep 2023
Cash from Financing (TTM) Benchmarks
Bruker Corp | -11.00M |
Azenta Inc | -452.51M |
Harvard Bioscience Inc | -12.13M |
Bionano Genomics Inc | 113.82M |
Singular Genomics Systems Inc | 0.696M |